The pandemic-induced transition to digital health is, according to the Nuffield Trust, contributing to an “inverse care law” that’s compounding existing health inequalities.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.